Chelsea Handler, Maintenance, and What Happens If You Stop

By
Published Updated Last reviewed
Medical lab testing image for Chelsea Handler, Maintenance, and What Happens If You Stop

Chelsea Handler's Public Ozempic Disclosure

In January 2023, Chelsea Handler confirmed on multiple platforms that she had been taking Ozempic. She was candid about the circumstances: an anti-aging doctor had prescribed it off-label for weight loss, not for type 2 diabetes, which remains semaglutide's FDA-approved indication under the Ozempic brand name. Handler stated she didn't initially realize what she had been prescribed, a detail she shared during a January 2023 appearance covered by People magazine.

What set Handler's disclosure apart from many celebrity GLP-1 stories was her openness about two specific facts. First, the prescribing physician was not an endocrinologist or obesity medicine specialist but an anti-aging practitioner. Second, she chose to discontinue the medication after learning more about it.

Handler's story became a reference point in the broader cultural conversation about off-label GLP-1 prescribing patterns. It raised questions the HealthRX Medical Team considers clinically important: what happens to patients who stop a GLP-1 receptor agonist after a period of use? And what does "maintenance" look like without the drug?

Off-Label Prescribing: Clinical Context

Semaglutide is approved under two brand names for two different indications. Ozempic (up to 2 mg weekly) carries an FDA approval for type 2 diabetes management. Wegovy (up to 2.4 mg weekly) holds the approval for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity.

When Handler's anti-aging doctor prescribed Ozempic for weight loss, that constituted off-label use. Off-label prescribing is legal and common across medicine, but it raises specific considerations. The dose ceiling differs between brands. Insurance coverage often depends on the approved indication. And prescriber expertise matters: an Endocrine Society clinical practice guideline on obesity pharmacotherapy emphasizes that medication management should include monitoring of metabolic parameters and structured follow-up, elements that may vary across practice settings.

Handler's experience put a public spotlight on prescribing patterns that obesity medicine specialists had been discussing privately for years. Patients receiving GLP-1 agonists outside of structured weight management programs may face gaps in monitoring, dose titration guidance, and discontinuation planning.

What the Research Shows About Stopping Semaglutide

The most cited data on GLP-1 discontinuation comes from the STEP 1 trial extension. In the STEP 1 trial extension study published in Diabetes, Obesity and Metabolism, participants who stopped semaglutide 2.4 mg after 68 weeks regained approximately two-thirds of their prior weight loss within one year. Cardiometabolic improvements in blood pressure, lipid panels, and waist circumference also partially reversed.

This pattern is not unique to semaglutide. A systematic review in Obesity Reviews examining multiple anti-obesity medications found that weight regain after discontinuation is the norm, not the exception, across drug classes. The biology is straightforward: GLP-1 receptor agonists suppress appetite through central and peripheral mechanisms. They slow gastric emptying, enhance satiety signaling in the hypothalamus, and reduce food-reward pathways. Remove the drug, and these effects fade within weeks.

The HealthRX Medical Team frames this as a key misconception in public discourse. Many patients (and some prescribers) treat GLP-1 agonists as a temporary intervention, something you take until you reach a goal weight and then stop. The clinical evidence does not support that framing. Obesity is classified as a chronic, relapsing disease by the American Medical Association, and the pharmacological tools that treat it generally require ongoing use to maintain their effects, much like statins for cholesterol or antihypertensives for blood pressure.

Handler's decision to stop is entirely valid as a personal choice. But clinically, the expectation should be that stopping will produce some degree of weight regain unless other interventions fill the gap.

The Biology of Rebound: Why Weight Returns

Weight regain after GLP-1 discontinuation is driven by several overlapping mechanisms. The hypothalamic appetite-regulation system adapts to weight loss by increasing hunger hormones. A study in The New England Journal of Medicine demonstrated that levels of ghrelin, GIP, and other appetite-regulating peptides remain altered for at least 12 months after diet-induced weight loss, creating persistent biological pressure to regain.

Semaglutide counteracts this pressure while it is active. The drug's half-life is approximately one week, meaning blood levels drop meaningfully within 2 to 3 weeks of the last injection. As drug levels fall, gastric emptying speeds return to baseline, satiety signaling diminishes, and caloric intake tends to increase, often without the patient consciously deciding to eat more.

Resting metabolic rate also plays a role. Weight loss from any cause reduces total energy expenditure. This metabolic adaptation, sometimes called "adaptive thermogenesis," has been documented in studies of contestants from The Biggest Loser and in controlled metabolic ward research published in Obesity. The combination of increased hunger signals and decreased energy expenditure creates a persistent caloric surplus that drives regain.

Maintenance Strategies After Discontinuation

At a glance

  • Weight regain is expected. Clinical data show most patients regain 50 to 70% of lost weight within 12 months of stopping semaglutide.
  • Exercise preserves lean mass. Resistance training during and after GLP-1 use helps retain muscle, which supports metabolic rate.
  • Dietary structure matters. High-protein diets (1.2 to 1.6 g/kg/day) have shown benefit for weight maintenance in post-weight-loss populations.
  • Dose reduction (not abrupt stop) may help. Some clinicians taper GLP-1 doses gradually, though this approach lacks large-scale trial data.
  • Switching to lower-intensity pharmacotherapy (e.g., oral semaglutide, metformin, or phentermine-topiramate) is sometimes used as a step-down, but evidence for this specific transition is limited.

For patients who stop a GLP-1 agonist, the HealthRX Medical Team recommends a structured transition plan rather than abrupt cessation. This should include baseline metabolic labs before discontinuation, a defined exercise prescription emphasizing resistance training at least 3 sessions per week, protein intake targets, and scheduled follow-up visits at 4, 12, and 24 weeks post-cessation.

The 2023 American Gastroenterological Association guideline on anti-obesity pharmacotherapy recommends long-term use for most patients who respond to treatment. For those who choose to stop, the guideline acknowledges limited evidence on optimal discontinuation protocols but underscores the importance of continued behavioral support.

The HealthRX Medical Team Take

Handler's story is a useful case study because it captures a pattern the HealthRX Medical Team sees frequently in clinical discussions. A patient receives a GLP-1 agonist outside of a structured obesity medicine program, experiences results, and then faces the question of what comes next without a clear plan.

Three clinical points stand out from Handler's public account:

Prescriber context shapes outcomes. Anti-aging clinics may prescribe GLP-1 agonists without the metabolic monitoring, nutritional counseling, and discontinuation planning that obesity medicine board-certified practitioners typically provide. This does not mean anti-aging doctors cannot prescribe responsibly. It means the infrastructure around the prescription matters as much as the drug itself.

Discontinuation should be planned, not reactive. Whether a patient stops because of side effects, cost, personal preference, or supply issues, the transition off a GLP-1 agonist benefits from a structured protocol. Abrupt stops, as Handler described her experience, leave patients without a metabolic safety net.

The "temporary tool" framing is clinically misleading. Public discourse often treats GLP-1 agonists as a short-term boost. The data consistently show that the biological drivers of obesity persist after the drug is removed. Patients deserve clear communication about this reality before starting treatment, not after they've already decided to stop.

Handler's willingness to discuss her experience publicly, including the off-label prescribing pathway and her decision to discontinue, added genuine transparency to a conversation that is often clouded by celebrity denials and vague references to "lifestyle changes."

Frequently asked questions

›
›
›
›
›

References

  • FDA Ozempic Label, https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209637lbl.pdf
  • FDA Wegovy Approval, https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-chronic-weight-management-first-2014
  • Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes Obes Metab. 2022. https://pubmed.ncbi.nlm.nih.gov/35441470/
  • Sumithran P et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011. https://www.nejm.org/doi/full/10.1056/NEJMoa1105816
  • Fothergill E et al. Persistent metabolic adaptation 6 years after The Biggest Loser. Obesity. 2016. https://pubmed.ncbi.nlm.nih.gov/27136388/
  • Westerterp-Plantenga MS et al. Dietary protein and weight maintenance. Br J Nutr. 2012. https://pubmed.ncbi.nlm.nih.gov/22935440/
  • AGA Clinical Practice Guideline on Pharmacological Interventions for Adults with Obesity. Gastroenterology. 2023. https://pubmed.ncbi.nlm.nih.gov/36882442/
  • Apovian CM et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015. https://academic.oup.com/jcem/article/100/2/342/2813109